



**Reinhard Schwartz-Albiez** currently works as a senior scientist at the clinical cooperation unit “Applied Tumor Immunology” at the German Cancer Research Center/National Center of Tumor Diseases in Heidelberg, Germany. He studied microbiology/immunology at the universities of Tübingen, Hamburg, Germany and Vancouver, British Columbia, Canada and for his PhD in biochemistry (1978-1982) at the University of Braunschweig, Germany. During his Postdoc time at the German Cancer Research Center and later as group leader (1984 – 2015) he performed research on cellular tumor immunology. In 1992 he habilitated in “Experimental Immunology” at the Faculty of Medicine of Heidelberg University. He is engaged in teaching at the University and is supervising MSc and PhD students since 1988. He devoted his major research to problems of human glycoimmunology. In particular, he described structure and function of distinct surface expressed glycoconjugates and enzymes of glycosylation of human lymphocytes and tumor cells. He was also responsible for the establishment of WHO-classified CD antigens/monoclonal antibodies defining glycan structures of normal and malignant hematopoietic cells. Many of these CD antibodies are nowadays in diagnostic use and some are even applied for therapeutic interventions. His current research interests comprise the field of natural anti-tumor cytotoxic antibodies and interactions between tumor cells and vascular endothelium. He founded a small Biotec company for development of new technologies for hematopoietic stem cell preparation in 1995 and in 2006 he was co-founder of “Serapeutics” for preparation of therapeutic anti-tumor natural antibodies. He is authors of more than 100 peer-reviewed publications, mainly in the field of glycobiology/immunology. He is currently involved as principal investigator in the EU M.Curie Training Network “Immunoshape” ([immunoshape.eu](http://immunoshape.eu)).

#### Selected recent references

Friedel M, André S, Goldschmidt H, Gabius HJ, [Schwartz-Albiez R](#). Galectin-8 enhances adhesion of multiple myeloma cells to vascular endothelium and is an adverse prognostic factor. *Glycobiology*. 2016 Jun 10. [Epub ahead of print].

Devarapu SK, Mamidi S, Plöger F, Dill O, Blixt O, Kirschfink M, [Schwartz-Albiez R](#). Cytotoxic activity against human neuroblastoma and melanoma cells mediated by IgM antibodies derived from peripheral blood of healthy donors. *Int J Cancer*. 2016 Jun 15;138(12):2963-73.

Engel P, Boumsell L, Balderas R, Bensussan A, Gattei V, Horejsi V, Jin BQ, Malavasi F, Mortari F, [Schwartz-Albiez R](#), Stockinger H, van Zelm MC, Zola H, Clark G. CD Nomenclature 2015: Human Leukocyte Differentiation Antigen Workshops as a Driving Force in Immunology. *J Immunol*. 2015 Nov 15;195(10):4555-63.

Mandal C, [Schwartz-Albiez R](#), Vlasak R. Functions and biosynthesis of O-acetylated sialic acids. *Top Curr Chem*. 2015;366:1-30. doi: 10.1007/128\_2011\_310. Review.

Moehler TM, Seckinger A, Hose D, Andrulis M, Moreaux J, Hielscher T, Willhauck-Fleckenstein M, Merling A, Bertsch U, Jauch A, Goldschmidt H, Klein B, Schwartz-Albiez R. The glycome of normal and malignant plasma cells. PLoS One. 2013 Dec 26;8(12):e83719.

Schauer R, Srinivasan GV, Wipfler D, Kniep B, Schwartz-Albiez R. O-Acetylated sialic acids and their role in immune defense. Adv Exp Med Biol. 2011;705:525-48. doi: 10.1007/978-1-4419-7877-6. Review.

Willhauck-Fleckenstein M, Moehler TM, Merling A, Pusunc S, Goldschmidt H, Schwartz-Albiez R. Transcriptional regulation of the vascular endothelial glycome by angiogenic and inflammatory signalling. Angiogenesis. 2010 Mar;13(1):25-42.

#### Contributions to textbooks

Schwartz-Albiez. Naturally occurring antibodies directed against carbohydrate tumor antigens In: Naturally occurring antibodies (H.U.Lutz, ed.), Springer 2012, pp. 27-39.

Schwartz-Albiez, R. Inflammation and glycosciences. In: The sugar code, Fundamentals of glycosciences (H.J.Gabius, ed.), Wiley-Blackwell, 2009, pp.-447-467.